Julia Zhang

Julia Zhang, M.D., Ph.D., is an Academic Clinical Associate Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine. She practices at the Fred Hutchinson Cancer Center at Overlake Cancer Center in Bellevue, Washington, where she provides specialized care in medical oncology and hematology.

Dr. Zhang completed her M.D. and Ph.D. training at Sun Yat-Sen University and Washington State University, respectively. She furthered her medical education with a residency in Internal Medicine at SUNY Downstate Medical Center and a fellowship in Hematology-Oncology at the University of Arkansas for Medical Sciences. She is board certified by the American Board of Internal Medicine in Internal Medicine, Hematology, and Medical Oncology.

Her clinical expertise encompasses general medical oncology and both benign and malignant hematology. Dr. Zhang's research interests span cancer biology, health disparities in oncology, autoimmune disorders, and liver diseases. She has contributed to significant research in areas including structural racism's impact on cancer mortality, autoimmune hepatitis manifestations related to COVID-19, and primary biliary cholangitis.

Dr. Zhang's publication record shows consistent scholarly activity with recent contributions in 2024, 2023, and 2020, demonstrating her engagement with both clinical practice and research. Her work spans multiple disciplines including oncology, hematology, hepatology, and public health, reflecting a broad research portfolio that addresses both specialized medical conditions and broader health system issues.

• Board Certified in Internal Medicine, Hematology, and Medical Oncology
• Active researcher with publications in high-impact journals
• Specialized expertise in complex oncological and hematological conditions

Dr. Zhang maintains an active clinical practice at the Fred Hutchinson Cancer Center while contributing to academic medicine through teaching and research. Her work bridges clinical care with scholarly investigation, particularly in areas where social determinants intersect with cancer outcomes.